{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:25:10Z","timestamp":1794489910094,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005036","name":"Universitetet i Bergen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2020,3,31]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In endometrioid endometrial cancer (EEC), current clinical algorithms do not accurately predict patients with lymph node metastasis (LNM), leading to both under- and over-treatment. We aimed to develop models that integrate protein data with clinical information to identify patients requiring more aggressive surgery, including lymphadenectomy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Protein expression profiles were generated for 399 patients using reverse-phase protein array. Three generalised linear models were built on proteins and clinical information (model 1), also with magnetic resonance imaging included (model 2), and on proteins only (model 3), using a training set, and tested in independent sets. Gene expression data from the tumours were used for confirmatory testing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>LNM was predicted with area under the curve 0.72\u20130.89 and cyclin D1; fibronectin and grade were identified as important markers. High levels of fibronectin and cyclin D1 were associated with poor survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.018), and with markers of tumour aggressiveness. Upregulation of both<jats:italic>FN1<\/jats:italic>and<jats:italic>CCND1<\/jats:italic>messenger RNA was related to cancer invasion and mesenchymal phenotype.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We demonstrate that data-driven prediction models, adding protein markers to clinical information, have potential to significantly improve preoperative identification of patients with LNM in EEC.<\/jats:p><\/jats:sec>","DOI":"10.1038\/s41416-020-0745-6","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:02:30Z","timestamp":1581292950000},"page":"1014-1022","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma"],"prefix":"10.1038","volume":"122","author":[{"given":"Hege F.","family":"Berg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenlin","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Myrvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine E.","family":"Fasmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari K.","family":"Halle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erling A.","family":"Hoivik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jone","family":"Trovik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingfrid S.","family":"Haldorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon B.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Krakstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrica M. J.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,10]]},"reference":[{"key":"745_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A. & Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"745_CR2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(05)67063-8","volume":"366","author":"F Amant","year":"2005","unstructured":"Amant, F., Moerman, P., Neven, P., Timmerman, D., Van Limbergen, E. & Vergote, I. Endometrial cancer. Lancet 366, 491\u2013505 (2005).","journal-title":"Lancet"},{"key":"745_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3802\/jgo.2011.22.1.3","volume":"22","author":"T Odagiri","year":"2011","unstructured":"Odagiri, T., Watari, H., Hosaka, M., Mitamura, T., Konno, Y., Kato, T. et al. Multivariate survival analysis of the patients with recurrent endometrial cancer. J. Gynecol. Oncol. 22, 3\u20138 (2011).","journal-title":"J. Gynecol. Oncol."},{"key":"745_CR4","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1093\/jnci\/djn397","volume":"100","author":"P Benedetti Panici","year":"2008","unstructured":"Benedetti Panici, P., Basile, S., Maneschi, F., Alberto Lissoni, A., Signorelli, M., Scambia, G. et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J. Natl Cancer Inst. 100, 1707\u20131716 (2008).","journal-title":"J. Natl Cancer Inst."},{"key":"745_CR5","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8","volume":"60","author":"WT Creasman","year":"1987","unstructured":"Creasman, W. T., Morrow, C. P., Bundy, B. N., Homesley, H. D., Graham, J. E. & Heller, P. B. Surgical pthological spread patterns of endometrial cancer. Cancer 60, 2035\u20132041 (1987).","journal-title":"Cancer"},{"issue":"Part 1","key":"745_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/AOG.0000000000000372","volume":"124","author":"KJ Yost","year":"2014","unstructured":"Yost, K. J., Cheville, A. L., Al-Hilli, M. M., Mariani, A., Barrette, B. A., McGree, M. E. et al. Lymphedema after surgery for endometrial cancer: prevalence, risk factors, and quality of life. Obstet. Gynecol. 124(Part 1), 307\u2013315 (2014).","journal-title":"Obstet. Gynecol."},{"key":"745_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0090-8258(88)90232-6","volume":"29","author":"A Ilancheran","year":"1988","unstructured":"Ilancheran, A. & Monaghan, J. M. Pelvic lymphocyst-a 10-year experience. Gynecol. Oncol. 29, 333\u2013336 (1988).","journal-title":"Gynecol. Oncol."},{"key":"745_CR8","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1006\/gyno.1997.4648","volume":"65","author":"P Benedetti-Panici","year":"1997","unstructured":"Benedetti-Panici, P., Maneschi, F., Cutillo, G., D\u2019Andrea, G., di Palumbo, V. S., Conte, M. et al. A randomized study comparing retroperitoneal drainage with no drainage after lymphadenectomy in gynecologic malignancies. Gynecol. Oncol. 65, 478\u2013482 (1997).","journal-title":"Gynecol. Oncol."},{"key":"745_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ygyno.2015.02.016","volume":"137","author":"M Zikan","year":"2015","unstructured":"Zikan, M., Fischerova, D., Pinkavova, I., Slama, J., Weinberger, V., Dusek, L. et al. A prospective study examining the incidence of asymptomatic and symptomatic lymphoceles following lymphadenectomy in patients with gynecological cancer. Gynecol. Oncol. 137, 291\u2013298 (2015).","journal-title":"Gynecol. Oncol."},{"key":"745_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00404-003-0488-7","volume":"270","author":"T Kuoppala","year":"2004","unstructured":"Kuoppala, T., Tomas, E. & Heinonen, P. K. Clinical outcome and complications of laparoscopic surgery compared with traditional surgery in women with endometrial cancer. Arch. Gynecol. Obstet. 270, 25\u201330 (2004).","journal-title":"Arch. Gynecol. Obstet."},{"key":"745_CR11","first-page":"2531","volume":"122","author":"IL Nesvold","year":"2002","unstructured":"Nesvold, I. L. & Fossa, S. D. Lymphedema after surgical treatment of cervical and vulvar cancer. Tidsskr. Nor. Laegeforen. 122, 2531\u20132533 (2002).","journal-title":"Tidsskr. Nor. Laegeforen."},{"key":"745_CR12","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1002\/cncr.22684","volume":"109","author":"V Beesley","year":"2007","unstructured":"Beesley, V., Janda, M., Eakin, E., Obermair, A. & Battistutta, D. Lymphedema after gynecological cancer treatment: prevalence, correlates, and supportive care needs. Cancer 109, 2607\u20132614 (2007).","journal-title":"Cancer"},{"key":"745_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(08)61766-3","volume":"373","author":"H Kitchener","year":"2009","unstructured":"Astec Study Group, Kitchener, H., Swart, A. M., Qian, Q., Amos, C. & Parmar, M. K. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373, 125\u2013136 (2009).","journal-title":"Lancet"},{"key":"745_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ygyno.2016.06.004","volume":"142","author":"K Imai","year":"2016","unstructured":"Imai, K., Kato, H., Katayama, K., Nakanishi, K., Kawano, A., Iura, A. et al. A preoperative risk-scoring system to predict lymph node metastasis in endometrial cancer and stratify patients for lymphadenectomy. Gynecol. Oncol. 142, 273\u2013277 (2016).","journal-title":"Gynecol. Oncol."},{"key":"745_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/jog.12309","volume":"40","author":"Y Todo","year":"2014","unstructured":"Todo, Y., Watari, H., Kang, S. & Sakuragi, N. Tailoring lymphadenectomy according to the risk of lymph node metastasis in endometrial cancer. J. Obstet. Gynaecol. Res. 40, 317\u2013321 (2014).","journal-title":"J. Obstet. Gynaecol. Res."},{"issue":"Suppl. 2","key":"745_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ijgo.12612","volume":"143","author":"F Amant","year":"2018","unstructured":"Amant, F., Mirza, M. R., Koskas, M. & Creutzberg, C. L. Cancer of the corpus uteri. Int. J. Gynaecol. Obstet. 143(Suppl. 2), 37\u201350 (2018).","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"745_CR17","unstructured":"Association TNM. Endometrial Cancer 2002. https:\/\/legeforeningen.no\/Fagmed\/Norsk-gynekologisk-forening\/Veileder-arkiv-utgatte-versjoner\/veileder-i-onkologisk-gynekologi-2002\/endometriecancer\/."},{"key":"745_CR18","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1016\/j.ejca.2013.06.016","volume":"49","author":"J Trovik","year":"2013","unstructured":"Trovik, J., Wik, E., Werner, H. M., Krakstad, C., Helland, H., Vandenput, I. et al. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. Eur. J. Cancer 49, 3431\u20133441 (2013).","journal-title":"Eur. J. Cancer"},{"key":"745_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-016-0506-0","volume":"18","author":"IS Haldorsen","year":"2016","unstructured":"Haldorsen, I. S. & Salvesen, H. B. What is the best preoperative imaging for endometrial cancer? Curr. Oncol. Rep. 18, 25 (2016).","journal-title":"Curr. Oncol. Rep."},{"key":"745_CR20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ygyno.2017.12.017","volume":"148","author":"B Geppert","year":"2018","unstructured":"Geppert, B., Lonnerfors, C., Bollino, M. & Persson, J. Sentinel lymph node biopsy in endometrial cancer\u2014feasibility, safety and lymphatic complications. Gynecol. Oncol. 148, 491\u2013498 (2018).","journal-title":"Gynecol. Oncol."},{"key":"745_CR21","doi-asserted-by":"publisher","first-page":"e353","DOI":"10.1016\/S1470-2045(12)70213-9","volume":"13","author":"HB Salvesen","year":"2012","unstructured":"Salvesen, H. B., Haldorsen, I. S. & Trovik, J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol. 13, e353\u2013e361 (2012).","journal-title":"Lancet Oncol."},{"key":"745_CR22","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00330-008-1271-8","volume":"19","author":"K Kitajima","year":"2009","unstructured":"Kitajima, K., Murakami, K., Yamasaki, E., Kaji, Y. & Sugimura, K. Accuracy of integrated FDG-PET\/contrast-enhanced CT in detecting pelvic and paraaortic lymph node metastasis in patients with uterine cancer. Eur. Radiol. 19, 1529\u20131536 (2009).","journal-title":"Eur. Radiol."},{"key":"745_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ajog.2016.11.1033","volume":"216","author":"AJ Bodurtha Smith","year":"2017","unstructured":"Bodurtha Smith, A. J., Fader, A. N. & Tanner, E. J. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. Am. J. Obstet. Gynecol. 216, 459\u2013476 (2017).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"745_CR24","unstructured":"Sentinel node biopsy in Low- and Intermediate Endometrial Cancer Management [Internet]. https:\/\/www.trialregister.nl\/trial\/5659."},{"key":"745_CR25","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1158\/1535-7163.MCT-06-0334","volume":"5","author":"R Tibes","year":"2006","unstructured":"Tibes, R., Qiu, Y., Lu, Y., Hennessy, B., Andreeff, M., Mills, G. B. et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 5, 2512\u20132521 (2006).","journal-title":"Mol. Cancer Ther."},{"key":"745_CR26","doi-asserted-by":"publisher","first-page":"7421","DOI":"10.1158\/1078-0432.CCR-07-0760","volume":"13","author":"BT Hennessy","year":"2007","unstructured":"Hennessy, B. T., Lu, Y., Poradosu, E., Yu, Q., Yu, S., Hall, H. et al. Pharmacodynamic markers of perifosine efficacy. Clin. Cancer Res. 13, 7421\u20137431 (2007).","journal-title":"Clin. Cancer Res."},{"key":"745_CR27","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"Cancer Genome Atlas N.","year":"2012","unstructured":"Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330\u2013337 (2012).","journal-title":"Nature"},{"key":"745_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","volume":"497","author":"N Cancer Genome Atlas Research","year":"2013","unstructured":"Cancer Genome Atlas Research, N., Kandoth, C., Schultz, N., Cherniack, A. D., Akbani, R., Liu, Y. et al. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67\u201373 (2013).","journal-title":"Nature"},{"key":"745_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4887","volume":"5","author":"R Akbani","year":"2014","unstructured":"Akbani, R., Ng, P. K., Werner, H. M., Shahmoradgoli, M., Zhang, F., Ju, Z. et al. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat. Commun. 5, 3887 (2014).","journal-title":"Nat. Commun."},{"key":"745_CR30","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1053\/j.seminoncol.2016.06.005","volume":"43","author":"Y Lu","year":"2016","unstructured":"Lu, Y., Ling, S., Hegde, A. M., Byers, L. A., Coombes, K., Mills, G. B. et al. Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. Semin. Oncol. 43, 476\u2013483 (2016).","journal-title":"Semin. Oncol."},{"key":"745_CR31","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1093\/bioinformatics\/btm283","volume":"23","author":"J Hu","year":"2007","unstructured":"Hu, J., He, X., Baggerly, K. A., Coombes, K. R., Hennessy, B. T. & Mills, G. B. Non-parametric quantification of protein lysate arrays. Bioinformatics 23, 1986\u20131994 (2007).","journal-title":"Bioinformatics"},{"key":"745_CR32","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1093\/bioinformatics\/btu736","volume":"31","author":"Z Ju","year":"2015","unstructured":"Ju, Z., Liu, W., Roebuck, P. L., Siwak, D. R., Zhang, N., Lu, Y. et al. Development of a robust classifier for quality control of reverse-phase protein arrays. Bioinformatics 31, 912\u2013918 (2015).","journal-title":"Bioinformatics"},{"key":"745_CR33","unstructured":"Smyth, G. K. in Bioinformatics and Computational Biology Solutions using R and Bioconductor.\u00a0Gentleman, R., Carey, V., Dudoit, S., Irizarry, R. & Huber, W. (eds). (Springer, New York, 2005)."},{"key":"745_CR34","doi-asserted-by":"crossref","unstructured":"Gentleman, R. Bioinformatics and Computational Biology Solutions Using R and Bioconductor (Springer, New York, Cambridge, 2005).","DOI":"10.1007\/0-387-29362-0"},{"key":"745_CR35","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1038\/bjc.2012.91","volume":"106","author":"C Krakstad","year":"2012","unstructured":"Krakstad, C., Trovik, J., Wik, E., Engelsen, I. B., Werner, H. M., Birkeland, E. et al. Loss of GPER identifies new targets for therapy among a subgroup of ERalpha-positive endometrial cancer patients with poor outcome. Br. J. Cancer 106, 1682\u20131688 (2012).","journal-title":"Br. J. Cancer"},{"key":"745_CR36","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/IGC.0000000000000367","volume":"25","author":"S Ytre-Hauge","year":"2015","unstructured":"Ytre-Hauge, S., Husby, J. A., Magnussen, I. J., Werner, H. M., Salvesen, O. O., Bjorge, L. et al. Preoperative tumor size at MRI predicts deep myometrial invasion, lymph node metastases, and patient outcome in endometrial carcinomas. Int. J. Gynecol. Cancer 25, 459\u2013466 (2015).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"745_CR37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00330-012-2575-2","volume":"23","author":"G Rechichi","year":"2013","unstructured":"Rechichi, G., Galimberti, S., Oriani, M., Perego, P., Valsecchi, M. G. & Sironi, S. ADC maps in the prediction of pelvic lymph nodal metastatic regions in endometrial cancer. Eur. J. Radiol. 23, 65\u201374 (2013).","journal-title":"Eur. J. Radiol."},{"key":"745_CR38","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejrad.2019.01.003","volume":"114","author":"T Wang","year":"2019","unstructured":"Wang, T., Gao, T., Yang, J., Yan, X., Wang, Y., Zhou, X. et al. Preoperative prediction of pelvic lymph nodes metastasis in early-stage cervical cancer using radiomics nomogram developed based on T2-weighted MRI and diffusion-weighted imaging. Eur. J. Radiol. 114, 128\u2013135 (2019).","journal-title":"Eur. J. Radiol."},{"key":"745_CR39","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s00330-017-5005-7","volume":"28","author":"Y Dong","year":"2018","unstructured":"Dong, Y., Feng, Q., Yang, W., Lu, Z., Deng, C., Zhang, L. et al. Preoperative prediction of sentinel lymph node metastasis in breast cancer based on radiomics of T2-weighted fat-suppression and diffusion-weighted MRI. Eur. J. Radiol. 28, 582\u2013591 (2018).","journal-title":"Eur. J. Radiol."},{"key":"745_CR40","doi-asserted-by":"publisher","first-page":"6904","DOI":"10.1158\/1078-0432.CCR-17-1510","volume":"23","author":"S Wu","year":"2017","unstructured":"Wu, S., Zheng, J., Li, Y., Yu, H., Shi, S., Xie, W. et al. A radiomics nomogram for the preoperative prediction of lymph node metastasis in bladder cancer. Clin. Cancer Res. 23, 6904\u20136911 (2017).","journal-title":"Clin. Cancer Res."},{"key":"745_CR41","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1002\/jmri.26184","volume":"48","author":"S Ytre-Hauge","year":"2018","unstructured":"Ytre-Hauge, S., Dybvik, J. A., Lundervold, A., Salvesen, O. O., Krakstad, C., Fasmer, K. E. et al. Preoperative tumor texture analysis on MRI predicts high-risk disease and reduced survival in endometrial cancer. J. Magn. Reson. Imaging 48, 1637\u20131647 (2018).","journal-title":"J. Magn. Reson. Imaging"},{"key":"745_CR42","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1177\/0284185117740932","volume":"59","author":"KE Fasmer","year":"2018","unstructured":"Fasmer, K. E., Bjornerud, A., Ytre-Hauge, S., Gruner, R., Tangen, I. L., Werner, H. M. et al. Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer. Acta Radiol. 59, 1010\u20131017 (2018).","journal-title":"Acta Radiol."},{"key":"745_CR43","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1074\/mcp.RA117.000291","volume":"17","author":"J Lee","year":"2018","unstructured":"Lee, J., Geiss, G. K., Demirkan, G., Vellano, C. P., Filanoski, B., Lu, Y. et al. Implementation of a multiplex and quantitative proteomics platform for assessing protein lysates using DNA-barcoded antibodies. Mol. Cell Proteom. 17, 1245\u20131258. (2018).","journal-title":"Mol. Cell Proteom."},{"key":"745_CR44","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1039\/C6TB02008A","volume":"5","author":"Z Han","year":"2017","unstructured":"Han, Z. & Lu, Z. R. Targeting fibronectin for cancer imaging and therapy. J. Mater. Chem. B 5, 639\u2013654. (2017).","journal-title":"J. Mater. Chem. B"},{"key":"745_CR45","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/onc.2013.118","volume":"33","author":"J Park","year":"2014","unstructured":"Park, J. & Schwarzbauer, J. E. Mammary epithelial cell interactions with fibronectin stimulate epithelial\u2013mesenchymal transition. Oncogene 33, 1649\u201357. (2014).","journal-title":"Oncogene"},{"key":"745_CR46","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1172\/JCI74778","volume":"124","author":"HA Kenny","year":"2014","unstructured":"Kenny, H. A., Chiang, C. Y., White, E. A., Schryver, E. M., Habis, M., Romero, I. L. et al. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J. Clin. Invest. 124, 4614\u201328. (2014).","journal-title":"J. Clin. Invest."},{"key":"745_CR47","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.yexcr.2015.02.019","volume":"333","author":"M Jeon","year":"2015","unstructured":"Jeon, M., Lee, J., Nam, S. J., Shin, I., Lee, J. E. & Kim, S. Induction of fibronectin by HER2 overexpression triggers adhesion and invasion of breast cancer cells. Exp. Cell Res. 333, 116\u2013126 (2015).","journal-title":"Exp. Cell Res."},{"key":"745_CR48","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/jid.2013.484","volume":"134","author":"J Zhu","year":"2014","unstructured":"Zhu, J. & Clark, R. A. F. Fibronectin at select sites binds multiple growth factors and enhances their activity: expansion of the collaborative ECM-GF paradigm. J. Invest. Dermatol. 134, 895\u2013901 (2014).","journal-title":"J. Invest. Dermatol."},{"key":"745_CR49","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nrc3090","volume":"11","author":"EA Musgrove","year":"2011","unstructured":"Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A. & Sutherland, R. L. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 11, 558\u2013572 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"745_CR50","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1128\/MCB.02124-05","volume":"26","author":"Z Li","year":"2006","unstructured":"Li, Z., Wang, C., Jiao, X., Lu, Y., Fu, M., Quong, A. A. et al. Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling. Mol. Cell. Biol. 26, 4240\u20134256 (2006).","journal-title":"Mol. Cell. Biol."},{"key":"745_CR51","doi-asserted-by":"crossref","first-page":"19704","DOI":"10.18632\/oncotarget.24803","volume":"9","author":"D Du","year":"2018","unstructured":"Du, D., Ma, W., Yates, M. S., Chen, T., Lu, K. H., Lu, Y. et al. Predicting high-risk endometrioid carcinomas using proteins. Oncotarget 9, 19704\u201319715. (2018).","journal-title":"Oncotarget"},{"key":"745_CR52","doi-asserted-by":"publisher","first-page":"10635","DOI":"10.3390\/ijms150610635","volume":"15","author":"A Kafka","year":"2014","unstructured":"Kafka, A., Tomas, D., Beros, V., Pecina, H. I., Zeljko, M. & Pecina-Slaus, N. Brain metastases from lung cancer show increased expression of DVL1, DVL3 and beta-catenin and down-regulation of E-cadherin. Int. J. Mol. Sci. 15, 10635\u201310651. (2014).","journal-title":"Int. J. Mol. Sci."},{"key":"745_CR53","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1158\/1078-0432.CCR-13-0594","volume":"19","author":"J Wang","year":"2013","unstructured":"Wang, J., Qian, J., Hoeksema, M. D., Zou, Y., Espinosa, A. V., Rahman, S. M. et al. Integrative genomics analysis identifies candidate drivers at 3q26-29 amplicon in squamous cell carcinoma of the lung. Clin. Cancer Res. 19, 5580\u20135590 (2013).","journal-title":"Clin. Cancer Res."},{"key":"745_CR54","doi-asserted-by":"crossref","unstructured":"Coopes, A., Henry, C. E., Llamosas, E. & Ford, C. E. An update of Wnt signalling in endometrial cancer and its potential as a therapeutic target. Endocr. Relat. Cancer.\u00a025, R647\u2013R662 (2018).","DOI":"10.1530\/ERC-18-0112"},{"key":"745_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4333-6","volume":"18","author":"T Banas","year":"2018","unstructured":"Banas, T., Pitynski, K., Okon, K. & Winiarska, A. Non-endometrioid and high-grade endometrioid endometrial cancers show DNA fragmentation factor 40 (DFF40) and B-cell lymphoma 2 protein (BCL2) underexpression, which predicts disease-free and overall survival, but not DNA fragmentation factor 45 (DFF45) underexpression. BMC Cancer 18, 418 (2018).","journal-title":"BMC Cancer"},{"key":"745_CR56","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-0943-03","volume":"10","author":"LK Mell","year":"2004","unstructured":"Mell, L. K., Meyer, J. J., Tretiakova, M., Khramtsov, A., Gong, C., Yamada, S. D. et al. Prognostic significance of E-cadherin protein expression in pathological stage I\u2013III endometrial cancer. Clin. Cancer Res. 10, 5546\u20135553 (2004).","journal-title":"Clin. Cancer Res."},{"key":"745_CR57","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1158\/1078-0432.CCR-10-2412","volume":"17","author":"J Trovik","year":"2011","unstructured":"Trovik, J., Wik, E., Stefansson, I. M., Marcickiewicz, J., Tingulstad, S., Staff, A. C. et al. Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin. Cancer Res. 17, 3368\u20133377 (2011).","journal-title":"Clin. Cancer Res."},{"key":"745_CR58","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1158\/1078-0432.CCR-15-0104","volume":"22","author":"JY Yang","year":"2016","unstructured":"Yang, J. Y., Werner, H. M., Li, J., Westin, S. N., Lu, Y., Halle, M. K. et al. Integrative protein-based prognostic model for early-stage endometrioid endometrial cancer. Clin. Cancer Res. 22, 513\u2013523 (2016).","journal-title":"Clin. Cancer Res."},{"key":"745_CR59","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1158\/1078-0432.CCR-15-0104","volume":"22","author":"JY Yang","year":"2016","unstructured":"Yang, J. Y., Werner, H. M. J., Li, J., Westin, S. N., Lu, Y., Halle, M. K., Trovik, J., Salvesen, H. B., Mills, G. B. & Liang, H. Integrative protein-based prognostic model for early stage endometrial cancer. Clin. Cancer Res. 22, 513\u2013523 (2016).","journal-title":"Clin. Cancer Res."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0745-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0745-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0745-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:07:31Z","timestamp":1684616851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0745-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,10]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,3,31]]}},"alternative-id":["745"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-0745-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,10]]},"assertion":[{"value":"9 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All parts of the study have been approved according to Norwegian legislation and Western Regional Committee for Medical and Health Research Ethics (REK 2009\/2315 and 2014\/1907) and according to the Institutional Review Board of MDACC (Lab08-0580). All included patients signed written informed consent. The study was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"N\/A","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was supported by the University of Bergen and the Norwegian Cancer Society. Investigators were supported by NIH K12 Calabresi Scholar Award (K12) to S.N.W., NCI SPORE in Uterine Cancer (2P50-06) to S.N.W., GBM and NCI Cancer Centre Support Grant (P30) to MD Anderson Cancer Centre. None of the funding sources were involved in collecting, analysing or interpreting data, nor writing the article or deciding to submit for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}